BRAFV600E protein expression and outcome from BRAF inhibitor treatment in BRAFV600E metastatic melanoma
Menée sur 58 patients atteints d'un mélanome métastatique présentant la mutation V600E du gène BRAF, cette étude évalue l'association entre le niveau d'expression de la protéine BRAFV600E, mesuré par immunohistochimie avant le traitement, et la réponse au dabrafenib ou au vemurafenib
Background: To examine the association between level and patterns of baseline intra-tumoural BRAFV600E protein expression and clinical outcome of BRAFV600E melanoma patients treated with selective BRAF inhibitors.
Methods: Fifty-eight BRAFV600E metastatic melanoma patients treated with dabrafenib or vemurafenib on clinical trials had pre-treatment tumour BRAFV600E protein expression immunohistochemically (IHC) assessed using the BRAF V600E mutant-specific antibody VE1. Sections were examined for staining intensity (score 1–3) and percentage of immunoreactive tumour cells, and from this an immunoreactive score (IRS) was derived (intensity × per cent positive/10). The presence of intra-tumoural heterogeneity for BRAFV600E protein expression was also assessed. BRAFV600E expression was correlated with RECIST response, time to best response (TTBR), progression-free survival (PFS) and overall survival (OS).
Results: Expression was generally high (median IRS 28 (range 5–30)) and homogeneous (78%). Expression of mutated protein BRAFV600E as measured by intensity, per cent immunoreactive cells, or IRS did not correlate with RECIST response, TTBR, PFS or OS, including on multivariate analysis. Heterogeneity of staining was seen in 22% of cases and did not correlate with outcome.
Conclusion: In the current study population, IHC-measured pre-treatment BRAFV600E protein expression does not predict response or outcome to BRAF inhibitor therapy in BRAFV600E metastatic melanoma patients.
British Journal of Cancer , résumé, 2012